Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke "MINOS"


Phase 1/2 Results

Eligibility Criteria

Inclusion Criteria

- over 18 years of age
- acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
- onset of symptoms less than 6 hours
- measurable neurologic deficit (National Institutes of Health [NIH] Stroke Scale >/= 1)

Exclusion Criteria

- allergy to tetracycline antibiotics
- women of child-bearing potential
- known hepatic and/or renal insufficiency
- Thrombocytopenia
- history of intolerance to minocycline
- dizziness at the time of stroke or in the past month (by self-report)
- aphasia likely to interfere with patients ability to report adverse effects
- previous functional disability
- stuporous or comatose
- presence of another serious illness likely to confound the study
- unlikely to be available for 90 day follow-up
- severe stroke (National Institutes of Health [NIH] Stroke Scale >22)
- undergoing an interventional neuro-radiological intervention in first 12 hour